BMS will continue to supply the acquired products until 2011 when it is anticipated that manufacture will transfer to GSK's Giza plant.
Deal Value (US$ Million) 23.2 Deal Type Acquisition Sub-Category Asset Purchase Deal Status Completed: 2009-07-02
Deal Participants
Target (Company) Bristol-Myers Squibb Company - Generics Business Acquirer (Company) GlaxoSmithKline plc Vendor (Company) Bristol-Myers Squibb Company
Deal Rationale
The acquisition represents GSK's strategy to accelerate growth in the emerging markets and extends its product portfolio in the Middle East and North Africa.

More News:
Market Updates |
Stock Alerts |
All Trading News |
Stock Index